Literature DB >> 6323640

Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.

R Feld, W K Evans, G DeBoer, I C Quirt, F A Shepherd, J L Yeoh, J F Pringle, D G Payne, J G Herman, D Chamberlain.   

Abstract

One hundred fifty-three patients with limited and 167 with extensive small cell carcinoma of the lung (SCCL) were evaluable for response to treatment with six courses of chemotherapy (cyclophosphamide, doxorubicin, and vincristine), irradiation to intrathoracic disease, and prophylactic cranial irradiation (PCI). No maintenance chemotherapy was given. Fifty-two percent of patients with limited disease (LD) and 10% of extensive disease patients (ED) achieved a complete response. The median survival times for LD and ED patients were 49 and 34 weeks, respectively. These results were compared to a previous experience with 147 patients who were treated with three courses of similar induction chemotherapy and thoracic irradiation, as well as one year of maintenance chemotherapy (CCNU, procarbazine, and methotrexate) but without PCI. Although the use of PCI was found to reduce the frequency of brain metastases as the site of first relapse, detailed comparisons of response rates and survival showed no significant differences between the two study populations. Prolonged maintenance chemotherapy of the type used in the first study does not favorably influence outcome after intensive induction therapy for SCCL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323640     DOI: 10.1200/JCO.1984.2.4.294

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  [Sequential induction chemotherapy and radiation treatment of inoperable small cell bronchial cancer. Results of a prospective randomized study].

Authors:  J Schütte; N Niederle; W Eberhardt; S Seeber; W Alberti; V Budach; H Hirche; C G Schmidt
Journal:  Klin Wochenschr       Date:  1989-12-04

Review 2.  Duration of chemotherapy in small cell lung cancer.

Authors:  S G Spiro; R L Souhami
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

Review 3.  Chemotherapy in lung cancer.

Authors:  C G Price; M L Slevin
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

4.  Chemotherapy for small cell lung cancer.

Authors:  S G Spiro
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09

5.  Short duration combination chemotherapy in the treatment of small cell lung cancer.

Authors:  A J Dorward; S W Banham; A W Hutcheon; S Ahmedzai; D Cunningham; A Gregor; M Soukop; B H Stack; N S Mackay; S B Kaye
Journal:  Thorax       Date:  1986-09       Impact factor: 9.139

Review 6.  Therapeutic procedure in small cell lung cancer.

Authors:  Anastasios Kallianos; Aggeliki Rapti; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Qiang Li; Haidong Huang; Bojan Zaric; Branislav Perin; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

7.  Patients at risk of chemotherapy-associated toxicity in small cell lung cancer.

Authors:  L Morittu; H M Earl; R L Souhami; C M Ash; J S Tobias; D M Geddes; P G Harper; S G Spiro
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

8.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study.

Authors:  C Gridelli; L Manzione; F Perrone; E Veltri; R Cioffi; M G Caprio; L Frontini; A Rossi; E Barletta; M L Barzelloni; D Bilancia; C Gallo
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

10.  Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

Authors:  W K Evans; B P Will; J M Berthelot; M C Wolfson
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.